edd/Vaccine

The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study.Lucinde RK, Karia B, Ouma N, Amadi D, Nyundo C, Mataza C, Nyaguara A, Scott JAG, Gallagher KE, Kagucia E
Vaccine, (2023). 41:666-675

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.Sparrow E, Adetifa I, Chaiyakunapruk N, Cherian T, Fell DB, Graham BS, Innis B, Kaslow DC, Karron RA, Nair H, Neuzil KM, Saha S, Smith PG, Srikantiah P, Were F, Zar HJ, Feikin D
Vaccine, (2022). 40:3506-3510

Unmet need for COVID-19 vaccination coverage in Kenya.Muchiri SK, Muthee R, Kiarie H, Sitienei J, Agweyu A, Atkinson PM, Edson Utazi C, Tatem AJ, Alegana VA
Vaccine, (2022). 40:2011-2019

Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review.Lucinde RK, Ong'ayo G, Houlihan C, Bottomley C, Goldblatt D, Scott JAG, Gallagher KE
Vaccine, (2021). 39:5095-5105

Coverage and timeliness of vaccination and the validity of routine estimates: Insights from a vaccine registry in Kenya.Adetifa IMO, Karia B, Mutuku A, Bwanaali T, Makumi A, Wafula J, Chome M, Mwatsuma P, Bauni E, Hammitt LL, Mataza C, Tabu C, Kamau T, Williams TN, Scott JAG
Vaccine, (2018). 36:7965-7974

Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection.Gerretsen HE, Capone S, Vitelli A, Reyes LS, Thompson A, Jones C, Green CA, Pollard AJ, Sande CJ
Vaccine, (2018). 36:6988-6994

A bibliometric analysis of systematic reviews on vaccines and immunisation.Fernandes S, Jit M, Bozzani F, Griffiths UK, Scott JAG, Burchett HED
Vaccine, (2018). 36:2254-2261

Carriage prevalence and serotype distribution of Streptococcus pneumoniae prior to 10-valent pneumococcal vaccine introduction: A population-based cross-sectional study in South Western Uganda, 2014.Nackers F, Cohuet S, le Polain de Waroux O, Langendorf C, Nyehangane D, Ndazima D, Nanjebe D, Karani A, Tumwesigye E, Mwanga-Amumpaire J, Scott JAG, Grais RF
Vaccine, (2017). 35:5271-5277

Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage.Ojal J, Hammitt LL, Gaitho J, Scott JAG, Goldblatt D
Vaccine, (2017). 35:4652-4657

Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data.Ojal J, Flasche S, Hammitt LL, Akech D, Kiti MC, Kamau T, Adetifa I, Nurhonen M, Scott JAG, Auranen K
Vaccine, (2017). 35:4561-4568

Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls.Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, Feikin DR, Groome MJ, Hajjeh RA, Johnson HL, Madhi SA, Mulholland K, O'Brien KL, Parashar UD, Patel MM, Rodrigues LC, Santosham M, Scott JA, Smith PG, Sommerfelt H, Tate JE, Victor JC, Whitney CG, Zaidi AK, Zell ER
Vaccine, (2017). 35:3295-3302

Case-control vaccine effectiveness studies: Data collection, analysis and reporting results.Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, Feikin DR, Groome MJ, Hajjeh RA, Johnson HL, Madhi SA, Mulholland K, O'Brien KL, Parashar UD, Patel MM, Rodrigues LC, Santosham M, Scott JA, Smith PG, Sommerfelt H, Tate JE, Victor JC, Whitney CG, Zaidi AK, Zell ER
Vaccine, (2017). 35:3303-3308

Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach.Pan-Ngum W, Kinyanjui T, Kiti M, Taylor S, Toussaint JF, Saralamba S, Van Effelterre T, Nokes DJ, White LJ
Vaccine, (2017). 35:403-409

Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya.Nyiro JU, Sande C, Mutunga M, Kiyuka PK, Munywoki PK, Scott JA, Nokes DJ
Vaccine, (2015). 33:1797-801

The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants.Sande CJ, Cane PA, Nokes DJ
Vaccine, (2014). 32:4726-9

Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group.Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, Henao-Restrepo AM, Leach AJ, Klugman KP, Porter BD, Sa-Leao R, Scott JA, Nohynek H, O'Brien KL, WHO Pneumococcal Carriage Working Group
Vaccine, (2013). 32:165-79

Strategic priorities for respiratory syncytial virus (RSV) vaccine development.Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS
Vaccine, (2013). 31 Suppl 2:B209-15

Spatial and socio-demographic predictors of time-to-immunization in a rural area in Kenya: Is equity attainable?.Moisi JC, Kabuka J, Mitingi D, Levine OS, Scott JA
Vaccine, (2010). 28:5725-30

Evaluation of a measles vaccine campaign in Ethiopia using oral-fluid antibody surveys.Nigatu W, Samuel D, Cohen B, Cumberland P, Lemma E, Brown DW, Nokes J
Vaccine, (2008). 26:4769-74

Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules.Wilson JN, Nokes DJ, Medley GF, Shouval D
Vaccine, (2007). 25:3705-12